Diligence memo · auto-generated · as of July 2, 2026
Hillhurst Biopharmaceuticals, Inc.
Hillhurst Biopharmaceuticals, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Hillhurst Biopharmaceuticals, Inc. operates in Biotechnology, based in MONTROSE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Hillhurst Biopharmaceuticals, Inc. has raised $1.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.8M on 2023-09-11.
Most recent recorded round closed around 2023-09-11.
Valuation (modeled)modeled
Provath models Hillhurst Biopharmaceuticals, Inc. at approximately $14M (range $1.3M–$46M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.98× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era. Within the normal band (98% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.8 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 26% of Biotechnology peers (4293 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.